Related Experiment Video
Updated: Mar 27, 2026
10:04
Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
Published on: March 13, 2018
12.7K
Quantitative Imaging in Cancer Clinical Trials
Thomas E Yankeelov1, David A Mankoff2, Lawrence H Schwartz3
1Institute of Imaging Science, Departments of Radiology and Radiological Sciences, Biomedical Engineering, Physics, and Cancer Biology, Vanderbilt University, Nashville, Tennessee. thomas.yankeelov@utexas.edu.
Summary
Quantitative imaging is crucial for assessing targeted cancer therapy response. Standardizing these methods in clinical trials will accelerate drug development and personalize patient care.
Area of Science:
- Oncology
- Medical Imaging
- Translational Research
Background:
- Targeted anticancer therapies require precise response assessment.
- Traditional imaging (CT, MRI) has limitations in evaluating early treatment effects.
- Biologic and physiologic questions necessitate advanced assessment methods.
Purpose of the Study:
- Elucidate the need for therapeutic response assessment in targeted therapy.
- Describe how quantitative imaging can provide relevant clinical data.
- Propose strategies for incorporating quantitative imaging into clinical trials.
Main Methods:
- Review of current needs in therapeutic response assessment.
- Description of quantitative imaging tools and methods.
- Examples of quantitative imaging application in clinical trials.
Main Results:
- Quantitative imaging offers scientifically and clinically relevant data for targeted therapies.
- Infrastructure improvements are needed to integrate quantitative imaging into trials.
- Standardized quantitative imaging can personalize cancer care.
Conclusions:
- Quantitative imaging is essential for evaluating targeted cancer therapies.
- Wider adoption of quantitative imaging in trials will improve drug development.
- Standardization of quantitative imaging will advance personalized oncology.
